| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | ||
|---|---|---|---|---|---|---|
Operating activities | ||||||
Net loss | ||||||
-21,312 | -23,637 | -33,415 | -14,586 | -9,029 | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
In process research and development exchanged for common stock | ||||||
12,151 | - | - | - | - | ||
Stock-based compensation | ||||||
118 | 4,131 | 5,273 | 1,718 | 284 | ||
Non cash interest related to convertible notes - related party | ||||||
- | - | - | 145 | 40 | ||
Non cash interest related to convertible notes – related party | ||||||
129 | - | - | 256 | 100 | ||
Non-cash discount amortization on convertible notes to related parties | ||||||
- | - | - | -17 | 62 | ||
Non-cash discount amortization on term loan | ||||||
- | 346 | 137 | -276 | 261 | ||
Revaluation of premium conversion derivative | ||||||
- | - | - | 850 | -297 | ||
Loss on note extinguishment – related party | ||||||
-1,114 | - | - | - | -198 | ||
Depreciation | ||||||
17 | - | - | - | - | ||
Non-cash interest upon conversion of convertible notes | ||||||
- | - | - | 649 | - | ||
Non-cash acquisition of in-process research and development | ||||||
- | - | - | - | 908 | ||
Change in assets and liabilities, net of the effects of the reverse asset acquisition: | ||||||
Prepaid expenses and other assets | ||||||
-824 | 196 | -198 | 55 | 10 | ||
Accounts payable | ||||||
-1,046 | -1,981 | 2,007 | 1,477 | 444 | ||
Accrued and other liabilities | ||||||
966 | -574 | -1,101 | 496 | 1,012 | ||
Net cash used in operating activities | ||||||
-7,039 | -21,911 | -26,901 | -11,043 | -5,433 | ||
Investing activities | ||||||
Cash acquired in connection with reverse asset acquisition | ||||||
1,525 | - | - | - | - | ||
Transaction costs in connection with reverse asset acquisition | ||||||
7,368 | - | - | - | - | ||
Purchases of property and equipment | ||||||
214 | - | - | - | - | ||
Net cash used in investing activities | ||||||
-6,057 | - | - | - | - | ||
Net cash used in operating activities | ||||||
-7,039 | -21,911 | -26,901 | -11,043 | - | ||
Financing activities | ||||||
Proceeds from issuance of redeemable preferred stock | ||||||
24,240 | - | - | - | - | ||
Proceeds from issuance of term loan and convertible notes | ||||||
- | - | 10,000 | 2,651 | 5,560 | ||
Proceeds from issuance of convertible notes to related parties | ||||||
- | - | - | 2,500 | 1,856 | ||
Issuance costs related to term loan and convertible notes | ||||||
- | 10 | 89 | 10 | - | ||
Repayment of principal | ||||||
- | -741 | - | - | - | ||
Proceeds from issuance of Series A convertible preferred stock | ||||||
- | - | - | - | 1,522 | ||
Exercise of stock options | ||||||
- | 84 | 41 | - | 3 | ||
Exercise of warrants | ||||||
- | - | 156 | - | - | ||
Exercise of stock options | ||||||
1 | 25,150 | 12,541 | 30,278 | - | ||
Issuance costs | ||||||
74 | 2,091 | 1,287 | 3,963 | 205 | ||
Deferred offering costs | ||||||
- | - | 21 | - | - | ||
Net cash provided by financing activities | ||||||
24,167 | 22,392 | 21,341 | 31,456 | 8,736 | ||
Net decrease in cash and restricted cash | ||||||
11,071 | - | - | - | - | ||
Net foreign exchange difference | ||||||
7 | - | - | - | - | ||
Net increase (decrease) in cash and cash equivalents | ||||||
- | 481 | -5,560 | 20,413 | 3,303 | ||
Supplemental disclosure of cash flow information: | ||||||
Cash paid for interest | ||||||
1 | 488 | 291 | - | 2 | ||
Supplemental non-cash financing transactions: | ||||||
Conversion of convertible notes to common stock | ||||||
548 | 196 | - | - | - | ||
Common stock and warrants issued in connection with the merger | ||||||
4,466 | - | - | - | - | ||
Net liabilities assumed in connection with the merger | ||||||
1,537 | - | - | - | - | ||
Unpaid transaction costs in accounts payable and accrued expenses related to the merger | ||||||
306 | - | - | - | - | ||
Exercise of premium conversion derivative | ||||||
- | - | - | - | 685 | ||
Redemption value change of Series A preferred stock | ||||||
- | - | - | 366 | 2,968 | ||
Issuance of common stock for acquisition of in-process research and development | ||||||
- | - | - | - | 908 | ||
Bifurcation of premium conversion derivative related to convertible notes | ||||||
- | - | - | 505 | 842 | ||
Convertible note extinguishment | ||||||
- | - | - | - | 1,426 | ||
Premium conversion derivative reduction upon convertible note extinguishment | ||||||
- | - | - | - | 182 | ||
Beneficial conversion feature related to convertible notes | ||||||
104 | - | - | 372 | - | ||
Operating lease right of use asset obtained in exchange for operating lease | ||||||
126 | - | - | - | - | ||
SeriesA and Series B Redeemable Convertible Preferred Stock | ||||||
Conversion of Series A and Series B preferred stock to common | ||||||
40,912 | - | - | - | - | ||
Conversion of Series A Preferred Stock | ||||||
Conversion of Series A preferred stock to common stock | ||||||
- | - | - | 8,319 | - | ||
Conversion of Convertible Notes | ||||||
Issuance of warrants in connection with term loan | ||||||
- | - | - | 11,445 | - | ||
Other Assets | ||||||
Offering costs in other assets paid in prior year | ||||||
- | - | - | 205 | - | ||
Accounts Payable and Accrued Liabilities | ||||||
Issuance costs in accounts payable and accrued liabilities | ||||||
- | - | 10 | - | - | ||